Navigate the critical balance of M&A, affordability, and alternative funding pathways shaping our global healthcare’s future Imagine a global chess match, where each move determines the trajectory of our healthcare system. On the chessboard are large pharmaceutical organizations, considered the vanguards of medical innovation, and the Federal Trade Commission (FTC). Their moves shape the intricate dynamics of the industry. The game’s strategic context centers on the decision-making strategies of large pharmaceutical companies, underpinned by a looming presence: antitrust regulations. Amidst this magnificent game, Pfizer’s Chief Development Officer, William Pao, articulates his concerns. Pao warns that stricter regulations may dampen the crucial M&A-dependent funding……
This article is free to read
Login to read the full article
Flavio Aliberti brings with him a 22-year track record in consulting around business intelligence, change management, strategy, M&A transformation, IT and SOX auditing for high regulated domains, like Insurance, Airlines, Trade Associations, Automotive, and Pharma. He holds an MSc in Space Aeronautic Engineering from the University of Naples and an MSc in Advanced Information Technology and Business Management from the University of Wales.